Alexander L Michael, 45Bethesda, MD

2022032, Oct 13, 2022

May 10, 2019

17/055190

- Leverkusen, DE
- Berlin, DE
Nuria ORTEGA HERNANDEZ - Wuppertal, DE
Frank SUESSMEIER - Muenchen, DE
Eloisa JIMENEZ NUNEZ - Freiburg im Breisgau, DE
Thomas BRUMBY - Berlin, DE
Niels LINDNER - Wuppertal, DE
Christoph GERDES - Koeln, DE
Elisabeth POOK - Wuppertal, DE
Anja BUCHMUELLER - Essen, DE
Fabienne Zdenka GAUGAZ - Uppsala, SE
Dieter LANG - Velbert, DE
Stefanie ZIMMERMANN - Duesseldorf, DE
Alexander Helmut Michael EHRMANN - Waltham MA, US
Michael GERISCH - Wuppertal, DE
Lutz LEHMANN - Berlin, DE
Andreas TIMMERMANN - Duesseldorf, DE
Martina SCHAEFER - Berlin, DE
Georg SCHMIDT - Wuppertal, DE
Karl-Heinz SCHLEMMER - Wupptertal, DE
Markus FOLLMANN - Koeln, DE
Elisabeth KERSTEN - Wuppertal, DE
Vivian WANG - Beijing, CN
Xiang GAO - Beijing, CN
Yafeng WANG - Beijing, CN

C07D 487/04
A61P 7/02

The invention relates to substituted dihydropyrazolo pyrazine carboxamide derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and diabetes, and also urogenital and ophthalmic disorders.

2023006, Mar 2, 2023

Nov 4, 2021

17/519329

- Leverkusen, DE
- Berlin, DE
Alexander Helmut Michael EHRMANN - Cambridge MA, US
Jens WILLWACHER - Biberach an der Riss, DE
David ENGEL - Wuppertal, DE
Andre Philippe DIESKAU - Wuppertal, DE
Antje KAHNERT - Wuppertal, DE
Alexey GROMOV - Erkrath, DE
Carsten SCHMECK - Mülheim, DE
Niels LINDNER - Wuppertal, DE
Thomas MÜLLER - Langenfeld, DE
Anna Lena ANDREEVSKI - Solingen, DE
Jan DREHER - Wuppertal, DE
Karl COLLINS - Düsseldorf, DE

Bayer Aktiengesellschaft - Leverkusen
Bayer Pharma Aktiengesellschaft - Berlin

C07D 403/14
C07D 401/14
C07D 405/14
C07D 413/14
C07D 487/04

The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.

2020005, Feb 20, 2020

Oct 9, 2017

16/341410

- Leverkusen, DE
- Berlin, DE
Alexander Helmut Michael EHRMANN - Cambridge MA, US
Jens WILLWACHER - Biberach an der Riß, DE
David ENGEL - Wuppertal, DE
Andre Philippe DIESKAU - Wuppertal, DE
Antje KAHNERT - Wuppertal, DE
Alexey GROMOV - Erkrath, DE
Carsten SCHMECK - Mülheim, DE
Niels LINDNER - Wuppertal, DE
Thomas MÜLLER - Langenfeld, DE
Anna Lena ANDREEVSKI - Solingen, DE
Jan DREHER - Wuppertal, DE
Karl COLLINS - Düsseldorf, DE

Bayer Aktiengesellschaft - Leverkusen
Bayer Pharma Aktiengesellschaft - Berlin

C07D 403/14
C07D 401/14
C07D 487/04
C07D 405/14
C07D 413/14

The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.